Neuralstem loses $3.2M in second quarter
Thursday, August 13, 2009
Washington Business Journal - by Tierney Plumb- Staff Reporter
Neuralstem Inc. widened its loss during the second quarter as it waits for Food and Drug Administration approval to start clinical trials for a treatment for Lou Gehrig’s disease.
The Rockville-based stem cell company reported a net loss of $3.2 million for the three months ended June 30, or 9 cents per share, compared with a net loss of $3 million, or 9 cents per share, for the comparable 2008 period.
Earnings were affected by a non-cash charge related to a change in accounting for certain warrants, offset in part by reductions in other expenses.
Cash, cash equivalents and short-term marketable securities at quarter’s end totaled $3.2 million, which Neuralstem estimates will be sufficient to meet its operating needs through the end of the year.
The company is waiting for the FDA’s decision on whether the agency will let Neuralstem go forward with the first human clinical trials of its stem cell treatments for amyotrophic lateral sclerosis, often referred to as Lou Gehrig’s disease.
“With the recent moratorium on all stem cell therapy imposed in China, we are now focusing our near term international efforts on commencing a clinical trial for stroke in Taiwan in the first half of 2010, with spinal cord injury trials in China and India commencing thereafter in 2010,” said Neuralstem CEO Richard Garr.
The company (NYSE Amex: CUR) said it has submitted a plan to address its non-compliance with stock market listing requirements.
http://www.bizjournals.com/washington/stories/2009/08/10/daily83.html?t=printable
~Best viewed with a positive attitude~